Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis
Open Access
- 1 January 2024
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 15
Abstract
Background: X-linked hypophosphatemia (XLH) is a rare, progressive disorder characterized by excess fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D synthesis. Burosumab is a recombinant human monoclonal antibody that inhibits FGF23, restoring patient serum phosphate levels. Safety data on long-term burosumab treatment are currently limited. Objectives: This post-authorization safety study (PASS) aims to monitor long-term safety outcomes in children and adolescents (1–17 years) treated with burosumab for XLH. This first interim analysis reports the initial PASS safety outcomes. Design: A 10-year retrospective and prospective cohort study. Methods: This PASS utilizes International XLH Registry (NCT03193476) data, which includes standard diagnostic and monitoring practice data at participating European centers. Results: At data cut-off (13 May 2021), 647 participants were included in the International XLH Registry; 367 were receiving burosumab, of which 67 provided consent to be included in the PASS. Mean (SD) follow-up time was 2.2 (1.0) years. Mean (SD) age was 7.3 (4.3) years (range 1.0–17.5 years). Mean duration of burosumab exposure was 29.7 (25.0) months. Overall, 25/67 participants (37.3%) experienced ⩾1 adverse event (AE) during follow-up; 83 AEs were reported. There were no deaths, no AEs leading to treatment withdrawal, nor serious AEs related to treatment. The most frequently reported AEs were classified as ‘musculoskeletal and connective tissue disorders’, with ‘pain in extremity’ most frequently reported, followed by ‘infections and infestations’, with ‘tooth abscess’ the most frequently reported. Conclusion: In this first interim analysis of the PASS, covering the initial 2 years of data collection, the safety profile of burosumab is consistent with previously reported safety data. The PASS will provide long-term safety data over its 10-year duration for healthcare providers and participants with XLH that contribute to improvements in the knowledge of burosumab safety. Trial registration: European Union electronic Register of Post-Authorisation Studies: EUPAS32190.Keywords
Funding Information
- Kyowa Kirin International plc
This publication has 16 references indexed in Scilit:
- Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialThe Lancet, 2019
- Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemiaNature Reviews Nephrology, 2019
- Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trialThe Lancet Diabetes & Endocrinology, 2019
- Pharmacological management of X‐linked hypophosphataemiaBritish Journal of Clinical Pharmacology, 2018
- Burosumab Therapy in Children with X-Linked HypophosphatemiaNew England Journal of Medicine, 2018
- Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complicationsEuropean Journal of Endocrinology, 2016
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- A clinician's guide to X-linked hypophosphatemiaJournal of Bone and Mineral Research, 2011
- Incidence and prevalence of nutritional and hereditary rickets in southern DenmarkEuropean Journal of Endocrinology, 2009
- What’s new in hypophosphataemic rickets?European Journal of Pediatrics, 2008